Geneva, Switzerland – Around 2,300 participants from across the world will meet in Geneva at the eighth European Lung Cancer Congress (ELCC 2018, 11-14 April 2018) to learn about and discuss the latest research in the field of lung cancer.
Organised by ESMO (European Society for Medical Oncology) and the IASLC (International Association for the Study of Lung Cancer), along with their partner societies ESTRO (European Society for Radiotherapy & Oncology) and ETOP (European Thoracic Oncology Platform), the ELCC Congress brings together some of the most important organisations in the field of thoracic oncology.
Key themes and programme highlights:
Immunotherapy: which line of treatment, combinations, biomarkers and mechanisms of resistance. Optimisation of targeted therapy in lung cancer First-line treatment of oncogene and non-oncogene addicted tumours New perspectives in the treatment of SCLC and mesothelioma including novel targets and an overview of the past, present, and future prospects for chemotherapy, radiotherapy and immunotherapy Latest advances in surgery and radiation therapy of lung cancer Implementation of lung cancer screening Molecular background of lung cancer and biomarkers of NSCLC Controversial topics: using off-label targeted agents for uncommon driver alterations; T790M: Liquid biopsy or histological samples?; Next generation TKI: front-line or later?
Article originally posted at